Samantha Shenoy, NP
Acute Care · San Francisco, CANPI 1083959811
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.4%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Johnson & Johnson at 36.2% of the total. 2025 is the largest year on record at $17,646, more than ten times the $1,236 reported in 2021. Among acute care clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 63 payments — averaging $490.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$11K
- Janssen Global Services, LLC$11K
- Janssen Scientific Affairs, LLC$4K
- Sanofi$2K
- Pfizer$810
- Regeneron$524
- plus $1K from 10 others
What the payments were for
- Consulting fees$16,83254%
- Speaking & faculty fees$2,6018%
- Grants$2,1717%
- Travel & lodging$7,40424%
- Food & beverage$1,9226%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 17 | $11,191 |
| Janssen Global Services, LLC | 12 | $11,169 |
| Janssen Scientific Affairs, LLC | 7 | $3,691 |
| Sanofi | 4 | $2,171 |
| Pfizer | 1 | $810 |
| Regeneron | 1 | $524 |
| Taiho Oncology, Inc. | 4 | $382 |
| AstraZeneca | 2 | $252 |
| Legend Biotech USA Inc. | 4 | $230 |
| AbbVie | 4 | $187 |
| Janssen Research & Development, LLC | 1 | $108 |
| Beigene USA, Inc. | 1 | $97 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $58 |
| Genmab U.S., Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $20 |
| Adaptive Biotechnologies Corporation | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,929 in reported general payments places this provider in the 95th percentile of 1,153 acute care providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atovaquone | 15 | $3,311 |
| Acyclovir | 62 | $1,771 |
| Testosterone | 12 | $653 |
| Gabapentin | 13 | $377 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $307 |
| Allopurinol | 13 | $136 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 43 | $123 |
Paid to pharmacies, not to this prescriber.
Other acute care in San Francisco
- Miranda SurjadiSan Francisco$26K
- Leslie PetersenCamarillo$370K
- Joyce KhremianSan Dimas$73K
- Eleanor VierraSacramento$64K
- Frances DyLos Angeles$57K
- Savannah HarrisVentura$56K
- Kori Ann JohnstonLos Angeles$42K
- Caroline KwongOrange$42K
- Gregory KnutzenColton$41K
- Sunita BoparaiLos Angeles$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.